Avelumab after chemotherapy for upper tract urothelial cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have upper tract urothelial cancer (cancer of the kidney or ureter) that has grown into the muscle or spread to lymph nodes, and you have already finished 3-4 rounds of cisplatin-based chemotherapy after surgery with no signs of cancer left.
- You are up and about (ECOG 0 or 1) and your blood counts, kidney function, and liver function are within certain limits.
- You have no active cancer spread, serious infections, autoimmune diseases requiring strong immune-suppressing drugs, or history of organ transplant.
- If you could become pregnant, you agree to use highly effective birth control during and for 30 days after the study drug.
- You have not had another cancer (except for cured ones), and you are willing to follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial is testing a system that helps doctors choose the best additional treatment for people with advanced upper tract urothelial cancer (UTUC) after their surgery. It focuses on patients whose cancer has spread into the muscle layer or beyond, or to nearby lymph nodes.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This trial tests whether a maintenance drug called avelumab can help keep metastatic bladder cancer from growing after patients have already responded to two prior treatments. It is for patients who had a specific sequence of therapies and whose cancer is stable after second-line chemotherapy.
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.